Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Molecular Glue Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GSPT1/eRF3a drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | GSPT1 Full-Length Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. GTP-binding domain intact. Ideal for Ternary Complex assays. | View GSPT1 Products |
| Antigen (Resistance Mutant) | GSPT1 G575N Mutant Protein. Key resistance mutation for selectivity validation. Theoretical MW verified. | View GSPT1 Products |
| Paralog Control | GSPT2 Full-Length Protein. For GSPT1 vs GSPT2 selectivity screening. HEK293 Expressed. | View GSPT2 Products |
| CRBN | Essential E3 ligase partner for molecular glue degrader assays. | View CRBN Products |
| Gene Delivery | GSPT1 Promise-ORF / Lentivirus Particles. Full-length ORF for stable reporter cell lines; pre-made high-titer particles for quick construction. | View GSPT1 Products |
| Benchmark Reference | Anti-GSPT1/eRF3a Recombinant Antibody. Validated for IP/Western blot and degradation tracking. | View GSPT1 Products |
| Validator | GSPT1 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View GSPT1 Products |
| Related Target: IKZF1 | Counter-screening target to ensure GSPT1 degrader selectivity. | View IKZF1 Products |
| Related Target: CEBPA | Translation regulation partner; synthetic lethality screening for AML applications. | View CEBPA Products |
| Related Target: MYC | c-MYC Recombinant Protein. Downstream pathway marker for GSPT1 degradation efficacy. | View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (CRBN-Glue-GSPT1) | High purity (>95%) recombinant GSPT1 and CRBN proteins optimized for SPR and TR-FRET. Full-length GSPT1 with intact GTP-binding domain; endotoxin <1EU/ug for sensitive cell assays. |
| Selectivity vs Paralog GSPT2 | Matched GSPT1 and GSPT2 protein pair with >95% purity; sequence verified by mass spec. |
| Off-Target Degradation Screening | Homolog/neo-substrate panel proteins (IKZF1/3) strictly verified by mass spec. |
| Resistance Mutation Analysis | GSPT1 G575N mutant available; critical for off-target and resistance mechanism studies. |
| Cellular Degradation Assays & Controls | High-titer Lentivirus for stable GSPT1-HiBiT or GFP reporter lines; benchmark antibodies included for precise degradation monitoring. |
| False Positives in Cellular Assays | Validated siRNA and neutralizing antibody included for specificity verification. |
Live GSPT1/eRF3a R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GSPT1 therapeutics is intensifying, with major players (Monte Rosa Therapeutics, BMS, Novartis) shifting focus from traditional enzymatic inhibitors to CRBN-dependent molecular glue degraders. First-generation therapies such as MRT-2359 (CC-90009) are advancing through Phase I/II trials in myeloid malignancies (AML, MDS) and MYC-driven solid tumors. The next wave of R&D targets highly selective GSPT1 degradation to maximize anti-tumor efficacy while avoiding hematopoietic toxicities from broader neo-substrate degradation (e.g., IKZF1/3) and GSPT2 cross-reactivity. Key challenges include overcoming resistance mutations at the G575 locus and optimizing paralog selectivity. Future combinations with BCL-2 or MEK inhibitors are under preclinical evaluation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue Degrader | Monte Rosa Therapeutics, BMS, Novartis, CelerisTx | NSCLC, Breast Cancer, AML, MDS | Ternary Complex SPR (Need full-length GSPT1 + G575N mutant + high-purity CRBN) |
| PROTACs | Blueprint Medicines, Various Biotechs | Solid Tumors, MYC-driven | Cell Permeability & Degradation Kinetics (Need Lentivirus reporter lines, specific benchmark antibodies) |
| Small Molecule / Covalent Inhibitor | Academic Consortia, Early Stage | Refractory Malignancies, Refractory Leukemia | Selectivity Assay (Need WT vs Mutant panel, binding site mapping) |